Palvella Therapeutics earnings date
Palvella Therapeutics (PI6) Q3 2026 Earnings Report
DE:PI6 Q3 2026 EPS Results
- Actual EPS
- -EUR 1.54
- Consensus EPS
- -EUR 1.62
- Beat/Miss
- Beat by +EUR 0.08
- One Year Ago EPS
- -EUR 0.93
DE:PI6 Q3 2026 Revenue Results
- Actual Revenue
- EUR 0
- Expected Revenue
- EUR 0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- Before Open
- Conference Call
- Thursday, November 5, 2026
Palvella Therapeutics's next earnings date is estimated for April 5, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, led by FDA acceptance of the QTORIN rapamycin NDA with priority review, a February 28, 2027 PDUFA date, strong physician and payer feedback, progress toward a commercial launch, and advancement across several rare-disease programs. The main negatives were the larger quarterly loss, increased operating expenses, planned near-term investment, the expected delay between early demand and revenue realization, lack of specific 2027 revenue guidance, and ongoing FDA discussions for the CVM trial design. Highlights significantly outweighed the lowlights.
Palvella expects FDA’s 6-month review goal for QTORIN rapamycin, with a PDUFA target action date of February 28, 2027, and, if approved, a launch in the first half of 27; more than 70% of surveyed physicians said they would prescribe, more than 70% expect to begin prescribing within 3 months of approval, about 70 people will be in the field at launch including approximately 40 frontline sales reps, with the team in place about 2 months ahead of the PDUFA date, and the company expects a broad label covering pediatric and adult use, all severities, and long term administration. Palvella expects more than 30 thousand diagnosed U.S. patients at $100 thousand to $200 thousand per patient per year, reaching $1 billion at peak with modest penetration, anticipates favorable coverage in the orphan pricing corridor, does not anticipate a bolus and expects steady growth quarter over quarter, expects early demand to be strong with revenue realization in line with other first in disease launches, and does not intend to provide specific 2027 revenue guidance. The company remains on track to initiate the Phase 3 cutaneous venous malformations study this quarter, expects to announce the study design at initiation, expects top line results from the Phase II LOTU-2 study in the second half of 27, remains on track to initiate the DSAP Phase 3 study this quarter, and expects existing cash to fund Palvella deep into the commercial launch.
- NDA Accepted and Priority Review GrantedThe FDA accepted Palvella's NDA for QTORIN rapamycin for microcystic lymphatic malformations and granted priority review, establishing a 6-month review goal instead of the standard 10-month review. The PDUFA target action date is February 28, 2027.
- Potential First FDA-Approved Therapy for Microcystic Lymphatic MalformationsQTORIN rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious rare disease for which there are currently no FDA-approved treatments. Palvella aims to establish it as a first-line treatment and standard of care if approved.
- Significant MLM Commercial OpportunityPalvella estimates more than 30 thousand diagnosed U.S. patients with microcystic lymphatic malformations and an attractive peak annual U.S. sales opportunity exceeding $1 billion. Ashley Kline said that reaching $1 billion at peak would require modest penetration at an estimated $100 thousand to $200 thousand per patient per year.
- Strong Physician Prescribing IntentIn market research involving more than 150 physicians, more than 70% said they would expect to prescribe QTORIN rapamycin if approved, and more than 70% expected to begin prescribing within 3 months of approval. Most planned to start several patients at once.
- Constructive Payer FeedbackInitial payer conversations were described as constructive. Payers viewed microcystic lymphatic malformations as a serious genetic vascular anomaly with unmet need, found the SELVA clinical data compelling, agreed that clinical diagnosis is appropriate, and indicated there would not be step-through therapy given the lack of FDA-approved treatment options. Palvella also anticipates favorable coverage in the orphan pricing corridor.
- Positive Clinical Profile and Physician ReceptionManagement said the product demonstrated 95% efficacy on the primary endpoint in its Phase 3 study. Clinicians reportedly find the clinical profile compelling, recognize the urgency to treat, and do not plan to watch and wait once the product is available. They also viewed QTORIN technology as a major differentiator because of its efficacy and apparent safety profile.
- Commercial Launch Infrastructure ProgressingPalvella expects approximately 70 commercial and medical affairs personnel to be in place at launch, including about 40 frontline sales representatives. The remaining team includes sales leaders, medical affairs personnel, patient access liaisons, field marketers, and inside sales. The company expects the team to be in place and trained before the late-February PDUFA date, with the frontline sales force expected to be in place about 2 months ahead of that date.
- In-House Patient Services OrganizationPalvella is building its own patient services organization to manage the patient experience from diagnosis through access and ongoing support. Management said recruiting is well advanced and that most of the team is expected to be onboard and trained before the PDUFA date.
- Expansion of Patient and Physician Identification EffortsPalvella used a large language model to analyze anonymized chart notes and identify novel treaters and ICD-10 coding patterns that were not visible in traditional claims analysis, indicating potential upside to internal market estimates. The algorithm is being deployed in the largest U.S. database of dermatology encounters.
- Disease Awareness and Digital Marketing ExecutionPalvella has launched its Beyond MLM disease-state awareness campaign in partnership with several patient advocacy groups and reported opt-in rates exceeding its internal forecast. The company is also using field activity, medical congresses, family-day events, and digital advertising on Meta, Reddit, Google, and other channels to educate patients and physicians.
- QTORIN Platform Supports Multiple Rare-Disease ProgramsManagement described QTORIN as a repeatable platform that delivers drugs directly into the skin while limiting systemic exposure and can leverage accumulated development knowledge across programs. The platform is intended to generate novel, IP-protected topical therapies for serious rare skin diseases and vascular anomalies.
- Cutaneous Venous Malformation Program AdvancingPalvella remains on track to initiate a Phase 3 study of QTORIN rapamycin for cutaneous venous malformations this quarter. The program has Fast Track designation, more than 75 thousand estimated diagnosed U.S. patients, and no FDA-approved therapies. In the Phase 2 TOIVA study, 73% of patients improved on the cVM-IGA at week 12, while 24-week data showed additional improvement on multiple endpoints and reduced disease severity and bleeding in pediatric patients.
- Angiokeratoma Program Shows Enrollment MomentumPalvella expects top-line results from the Phase 2 LOTU-2 study in clinically significant angiokeratomas in the second half of 2027. The 12-week baseline-control study is evaluating once-daily QTORIN rapamycin in about 15 patients, with management reporting strong enrollment momentum and site engagement. Market research with 50 physicians found that 96% would incorporate QTORIN rapamycin into their practice if approved.
- DSAP Program Progresses Toward Clinical TestingQTORIN-pitavastatin for disseminated superficial actinic porokeratosis has completed formulation development and multiple IND-enabling toxicology studies. Palvella established pharmacodynamic proof of principle showing that pitavastatin reversed hyperproliferation in a human porokeratosis cell model, licensed a U.S. patent from Yale, filed additional IP, and remained on track to initiate a Phase 3 study this quarter.
- Strong Interest in DSAP TrialA new claims analysis identified approximately 155 thousand diagnosed U.S. DSAP patients. Palvella has received more than 90 unsolicited patient requests about the trial, and management said study investigators continue to reiterate the disease's unmet need.
- Four Potential First-in-Disease OpportunitiesPalvella identified more than 30 thousand diagnosed U.S. patients with microcystic lymphatic malformations, more than 75 thousand with cutaneous venous malformations, more than 50 thousand with clinically significant angiokeratomas, and greater than 50 thousand with DSAP. Management believes each indication could potentially support a first FDA-approved therapy and a multibillion-dollar U.S. total addressable market based on estimated prevalence and orphan pricing.
- Cash Runway Supports Planned OperationsAs of the end of the third quarter, Palvella reported $237 million in cash equivalents and short-term investments, compared with $250 million at the end of the second quarter. Management said existing cash is expected to fund the company deep into the commercial launch, including a fully funded standalone U.S. launch, the Phase 3 CVM program, the angiokeratoma and DSAP programs, and continued QTORIN platform expansion.
- Capital Efficiency and 505(b)(2) AdvantagesManagement attributed capital efficiency to a lean operating model, the 505(b)(2) regulatory pathway, lower pharmacology risk than a new chemical entity, and the ability to reuse QTORIN platform knowledge and expertise across programs. The company said 2026 cash expenses have been below previous expectations and that full-year spending will likely be below previous guidance.
DE:PI6 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 05, 2027 | 2026 (Q4) | -1.78- | -1.09 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -1.62-1.54 | -0.93 | -65.05% (-0.61) | |
| Aug 04, 2026 | 2026 (Q2) | -1.06-1.38 | -0.78 | -76.74% (-0.60) | |
| May 07, 2026 | 2026 (Q1) | ―-1.09 | -0.67 | -62.16% (-0.42) | |
| Mar 31, 2026 | 2025 (Q4) | -0.85-1.09 | -0.67 | -62.16% (-0.42) | |
| Nov 11, 2025 | 2025 (Q3) | -0.76-0.93 | -1.07 | 12.71% (+0.14) | |
| Aug 14, 2025 | 2025 (Q2) | -0.67-0.78 | -2.51 | 68.89% (+1.73) | |
| May 15, 2025 | 2025 (Q1) | ―-0.67 | -3.59 | 81.28% (+2.92) | |
| Mar 31, 2025 | 2024 (Q4) | -1.10-0.67 | -3.59 | 81.28% (+2.92) | |
| May 08, 2024 | 2024 (Q1) | ―-3.59 | -13.06 | 72.54% (+9.48) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
